The life sciences community is a powerful force determined to bring hope and healing to people around the world through relentless research and exploration.
The recent hospitalisation of Madonna once again highlights the risks posed by bacterial infections and their potentially serious consequences for patients.
As the industry has transitioned much of its R&D expertise into large molecule therapies, an emerging approach could provide a revolutionary treatment tool.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
